Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
450
Belzutifan is administered orally at 120 mg once daily (qd) OR 200 mg qd until progressive disease (PD), unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Nivolumab is administered intravenously at 480 mg until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Lenvatinib is administered orally at 20 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Cabozantinib is administered orally at 60 mg qd until PD, unacceptable toxicity, withdrawal of consent, death, investigator decision, or study termination.
Beth Israel Deaconess Medical Center ( Site 0107)
Boston, Massachusetts, United States
RECRUITINGDana-Farber Cancer Institute ( Site 0105)
Boston, Massachusetts, United States
RECRUITINGKarmanos Cancer Center ( Site 0108)
Detroit, Michigan, United States
RECRUITINGHospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100)
Philadelphia, Pennsylvania, United States
Cohort A and Cohort B: Overall Survival (OS)
Overall survival is defined as the time from randomization or the first dose of any study intervention in the parent study to death due to any cause.
Time frame: Up to approximately 7 years
Number of Participants Who Experience One or More Adverse Events (AE)
An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
Time frame: Up to approximately 2 years
Number of Participants Who Discontinued Study Intervention Due to an AE
An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
Time frame: Up to approximately 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
SCRI Oncology Partners ( Site 7000)
Nashville, Tennessee, United States
RECRUITINGSTART San Antonio ( Site 0104)
San Antonio, Texas, United States
RECRUITINGFred Hutchinson Cancer Center ( Site 0106)
Seattle, Washington, United States
RECRUITINGSt George Hospital-Oncology Clinical Research Unit ( Site 2701)
Kogarah, New South Wales, Australia
RECRUITINGWestmead Hospital ( Site 2703)
Sydney, New South Wales, Australia
RECRUITINGFrankston Hospital-Oncology and Haematology ( Site 2705)
Frankston, Victoria, Australia
RECRUITING...and 44 more locations